Why the study?
Does pharmacological therapy reduce the risk of stroke and coronary heart disease in patients with mild to moderate hypertension?
Does pharmacological therapy reduce the risk of stroke and coronary heart disease in patients with mild to moderate hypertension?
Pharmacological therapy for mild to moderate hypertension significantly reduces the risk of stroke, with a smaller but possible reduction in coronary heart disease.
Answers are grounded in this paper and cite their sources.
Supports BP lowering in mild-moderate hypertension for stroke prevention; leaves open precise CHD benefits and targets in contemporary practice.
MANY CLINICIANS consider a sufficiently high risk of stroke to be the clearest indication for pharmacological therapy of patients with mild to moderate hypertension. The rationale is derived from several recent overviews or meta-analyses of data from randomized trials. For stroke, there are clear reductions of about 40%, whereas for coronary heart disease (CHD), there are possible reductions of 9% to 14%.¹⁻³In those trials, the magnitude of the reduction in diastolic blood pressure (DBP) was 5 to 6 mm Hg, and the duration of treatment was about 3 to 5 years. In observational studies, such changes in DBP over longer periods are associated with about a 40% decrease in stroke but 20% to 25% reductions in risk of CHD.³,⁴ Several possible explanations have been offered for the smaller risk reductions in CHD observed in trials than predicted in observational studies. First, the beneficial effects on stroke may
No takes yet. Share an insight, caveat, or question.
P. R. Hebert (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: